Trifarotene
- Generic Name
- Trifarotene
- Brand Names
- Aklief
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33NO4
- CAS Number
- 895542-09-3
- Unique Ingredient Identifier
- 0J8RN2W0HK
- Background
Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. Retinoids are a class of medications structurally and functionally analogous to vitamin A, though later generation retinoids such as trifarotene and adapalene bear little structural resemblance to vitamin A and ...
- Indication
Trifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
- Associated Conditions
- Acne Vulgaris
- Associated Therapies
- -
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 47
- Registration Number
- NCT03915860
- Locations
- 🇺🇸
Galderma Investigational Site, Richardson, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath